Figlin Kidney Cancer

Erscheinungsjahr 2012
ISBN: 978-1-4615-0451-1
Verlag: Springer US
Format: PDF
Kopierschutz: 1 - PDF Watermark

E-Book, Englisch, Band 116, 246 Seiten, eBook

Reihe: Cancer Treatment and Research

Kidney cancer is a heterogenous disease. This book covers: -new surgical approaches which are becoming the standard, i.e., nephon sparing, laporascopic, minimally invasive techniques; -new staging and prognostic capabilities; -evolving therapeutic options include, cell based vaccine, gene and antibody therapy; -molecular genetics allow for a better understanding of the various types of kidney cancer. Kidney Cancer is a comprehensive review covering present and future surgical approaches, staging and prognostic factors, currently accepted and future plans for prevention, diagnosis and treatment. Contributing authors to this book are internationally recognized specialists in this disease. This book will be useful to the specialist (oncologist and urologist), primary care physicians, patients and family members dealing with kidney cancer.

Zielgruppe

Research

Autoren/Hrsg.

Figlin, Robert A.

Inhaltsverzeichnis

I. Introduction.- 1. Molecular Genetics of Kidney Cancer.- 2. Mechanisms of Immune Dysfunction in Renal Cell Carcinoma.- 3. New Algorithms for the Staging of Kidney Cancer.- 4. Basic Biology and Clinical Behavior of Kidney Cancer.- II. Kidney Cancher.: Surgical Approaches.- 5. Nephron Sparing Surgery.- 6. Laparoscopic Radical Nephrectomy AND Minimally Invasive Surgery for Kidney Cancer.- 7. Role of Nephrectomy in Metastatic Kidney Cancer.- III. Metastatic Renal Cell Carcinoma: Current and Future Approaches.- 8. Prognostic Factors for Metastatic Kidney Cancer.- 9. Interleukin-2 Based Therapy for Kidney Cancer.- 10. The Role of Systemic Chemotherapy in the Treatment of Kidney Cancer.- 11. Cell, Gene, and Vaccine Based Strategies in Kidney Cancer.- 12. Monoclonal Antibody Therapy of Kidney Cancer.- 13. Allogeneic Hematopoetic Stem Cell Transplantation for Cytokine Refractory Renal Cell Carcinoma.- 14. Novel Therapies for Renal Cell Carcinoma.

Über Autor(innen)

Robert A. Figlin , Professor of Medicine, Urology, Departments of Medicine and Urology, Division of Hematology/Oncology, University of California, Los Angeles School of Medicine, USA, holds the Henry Alvin and Carrie L. Meinhardt Chair in Urologic Oncology. He serves as Medical Director of the Thoracic and Genitourinary Oncology Program. He is a Senior Clinical Investigator in areas of genitourinary and thoracic oncology and has served as Principal Investigator on Phase I, II, and III trials. He serves as Chairman of the UCLA Medical Institutional Review Board and as a member of the UCLA Human Research Policy Board.